Nutex Health (US:NUTX) Globenewswire·2025-09-11 22:44Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for October 21, 2025 [3][5]. Group 1: Allegations Against Nutex - The complaint alleges that Nutex and its executives made false and misleading statements, failing to disclose a coordinated scheme to defraud insurance companies through HaloMD [5]. - It is claimed that revenues from HaloMD's engagement were unsustainable due to fraudulent conduct, and Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting [5]. - Nutex is accused of improperly calculating stock-based compensation obligations, which increased the risk of failing to file timely financial reports with the SEC [5]. Group 2: Market Reaction - Following the release of a short report by Blue Orca Capital, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [6][7]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price dropped further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [8]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [9]. - Faruqi & Faruqi encourages individuals with information regarding Nutex's conduct to come forward, including whistleblowers and former employees [10].